Gemcitabine and cisplatin salvage regimen in heavily pretreated metastatic breast cancer: A Brazilian experience

Medical Oncology

Volumn 28, Issue SUPPL. 1, 2011, Pages

  De Lima Araújo, Luiz Henrique ^a   Moitinho, Marcos Veloso ^a   Silva, Ana Maria Fantini ^a   Gomes, Cleudes Alice Sousa ^a   Noronha Júnior, Hélio ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Cisplatin; Gemcitabine; Metastatic breast cancer; Predictive; Retrospective

Indexed keywords

ANTHRACYCLINE; BILIRUBIN; CISPLATIN; CREATININE; DEXAMETHASONE; GEMCITABINE; HORMONE RECEPTOR; ONDANSETRON; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAZIL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; ECOG PERFORMANCE STATUS SCALE; FEMALE; HUMAN; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PREMEDICATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RATING SCALE; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84655174927     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9654-5     Document Type: Article

References (17)

1. A Jemal R Siegel E Ward 2009 Cancer statistics 2009 CA Cancer J Clin 59 4 225 249
2. Instituto Nacional de Câncer/Ministério da Saúde. Estimativa 2010: incidência de câncer no Brasil. Rio de Janeiro: INCA. [Last access in 05/04/2010]. Available at: http://www.inca.gov.br.
3. RA Nagourney JS Link JB Blitzer 2000 Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients J Clin Oncol 18 2245 2249 (Pubitemid 30350216)
4. V Heinemann HJ Stemmler A Wohlrab 2006 High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer Cancer Chemother Pharmacol 57 640 646 (Pubitemid 43237849)
5. JH Seo SC Oh CW Choi 2007 Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer Cancer Chemother Pharmacol 59 269 274 (Pubitemid 44885156)
6. TZM Mohran 2004 Gemcitabine and cisplatin combination chemotherapy as a first-line treatment in patients with metastatic breast cancer J Egypt Natl Cancer Inst 16 1 8 14
7. PA Burch JA Mailliard DW Hillman 2005 Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial Am J Clin Oncol 28 2 195 200
8. HK Chew JH Doroshow P Frankel 2009 Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer J Clin Oncol 27 13 2163 2169
9. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors JNCI 92 3 205 216 (Pubitemid 30099779)
10. EL Kaplan P Meier 1958 Nonparametric estimation for incomplete observation J Am Stat Assoc 53 457 481
11. Lawless JS. Statistical models and methods for life-time data. New York: Wiley; 1982.
12. DR Cox 1972 Regression models and life tables J R Stat Soc 34 187 220
13. TD Shanafelt C Loprinzi R Marks 2004 Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 22 1966 1974 (Pubitemid 41095190)
14. HR Kim MS Kang II Na 2010 The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients J Cancer Res Clin Oncol 136 4 547 552
15. EN Imyanitov 2009 Breast cancer therapy for BRCA1 carriers: moving towards platinum standard? Hered Cancer Clin Pract 7 1 8 10
16. Byrski T, Foszczynska-Kloda M, Huzarski T, et al. Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC). J Clin Oncol 2009;27:15s (suppl; abstr 1099).
17. J Bines A Eniu 2008 Effective but cost-prohibitive drugs in breast cancer treatment. A clinician's perspective Cancer 113 8 2353 2358